Literature DB >> 26157044

Activation of Mas Oncogene-Related G Protein-Coupled Receptors Inhibits Neurochemical Alterations in the Spinal Dorsal Horn and Dorsal Root Ganglia Associated with Inflammatory Pain in Rats.

Dongmei Wang1, Peizhong Wang1, Jianping Jiang1, Qingqin Lv1, Xueai Zeng1, Yanguo Hong2.   

Abstract

Mas oncogene-related G protein-coupled receptor C (MrgC) is unequally expressed in sensory ganglia and has been shown to modulate pathologic pain. This study investigated the mechanism underlying the effect of MrgC receptors on inflammatory pain. Intrathecal administration of the selective MrgC receptor agonist bovine adrenal medulla 8-22 (BAM8-22) (30 nmol) inhibited complete Freund's adjuvant-evoked hyperalgesia. This was associated with the inhibition of protein kinase C-γ and phosphorylated extracellular signal-regulated protein kinase in the spinal cord and/or dorsal root ganglia (DRG). The complete Freund's adjuvant injection in the hindpaw induced an increase in Gq, but not Gi and Gs, protein in the spinal dorsal horn. This increase was inhibited by the intrathecal administration of BAM8-22. The exposure of DRG cultures to bradykinin (10 μM) and prostaglandin E2 (1 μM) increased the expression of calcitonin gene-related peptide (CGRP) and neuronal nitric oxide synthase in small- and medium-sized neurons as well as the levels of CGRP, aspartate, and glutamate in the cultured medium. The bradykinin/prostaglandin E2-induced alterations were absent in the presence of BAM8-22 (10 nM). These results suggest that the activation of MrgC receptors can modulate the increase in the expression of CGRP and neuronal nitric oxide synthase as well as the release of CGRP and excitatory amino acids in DRG associated with inflammatory pain. This modulation results in the inhibition of pain hypersensitivity by suppressing the expression of Gq protein and protein kinase C-γ and extracellular signal-regulated protein kinase signaling pathways in the spinal cord and/or DRG. The present study suggests that MrgC receptors may be a novel target for relieving inflammatory pain.
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26157044     DOI: 10.1124/jpet.115.225672

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  The Ubiquitination of Spinal MrgC Alleviates Bone Cancer Pain and Reduces Intracellular Calcium Concentration in Spinal Neurons in Mice.

Authors:  Yu-E Sun; Hua-Ye Xu; Jing Hao; Wen-Wen Huo; Yue Qian; Bai-Ling Hou
Journal:  Neurochem Res       Date:  2019-09-12       Impact factor: 3.996

2.  Rostral Ventrolateral Medulla EP3 Receptor Mediates the Sympathoexcitatory and Pressor Effects of Prostaglandin E2 in Conscious Rats.

Authors:  Samar Rezq; Abdel A Abdel-Rahman
Journal:  J Pharmacol Exp Ther       Date:  2016-08-29       Impact factor: 4.030

3.  Mas-Related Gene (Mrg) C Activation Attenuates Bone Cancer Pain via Modulating Gi and NR2B.

Authors:  Yu'e Sun; Ming Jiang; Bailing Hou; Cui'e Lu; Yishan Lei; Zhengliang Ma; Xiaoping Gu
Journal:  PLoS One       Date:  2016-05-06       Impact factor: 3.240

4.  Electroacupuncture Alleviates Experimental Chronic Inflammatory Pain by Inhibiting Calcium Voltage-Gated Channel-Mediated Inflammation.

Authors:  Jie Zhou; Ying Jin; Ruijie Ma; Hongyun Song; Qin Chen; Yueyang Chai; Yi Liang; You Zhou; Jianqiao Fang
Journal:  Evid Based Complement Alternat Med       Date:  2020-02-10       Impact factor: 2.629

Review 5.  The signaling pathway and polymorphisms of Mrgprs.

Authors:  Haley R Steele; Liang Han
Journal:  Neurosci Lett       Date:  2020-12-31       Impact factor: 3.046

6.  Involvement of MrgprC in Electroacupuncture Analgesia for Attenuating CFA-Induced Thermal Hyperalgesia by Suppressing the TRPV1 Pathway.

Authors:  Ying-Jun Liu; Xiao-Xi Lin; Jian-Qiao Fang; Fang Fang
Journal:  Evid Based Complement Alternat Med       Date:  2018-02-12       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.